Immuneering Corp. Class A (IMRX)
NASDAQ:IMRX
Want to see IMRX full AI Analyst Report?
IMRX Stock Chart & Stats
$5.56
-$0.24(-10.17%)
At close: 4:00 PM EST
$5.56
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$1.58 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)1.09M
Market Cap
$348.72M
Enterprise Value-$43.40B
Total Cash (Recent Filing)$156.69B
Total Debt (Recent Filing)$3.73B
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding64,697,230
10 Day Avg. Volume1,674,041
30 Day Avg. Volume1,092,987
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap-124.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit49.03K
Enterprise Value/Ebitda737.34
Forecast
1Y Price Target
$17.00Price Target Upside205.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary AI-driven PlatformA proprietary computational biology and AI platform is a durable competitive asset that can increase discovery throughput and reduce time and cost per candidate. Over 2–6 months this underpins pipeline productivity, supports multiple programs, and makes partnerships or licensing more feasible.
Advancing Late-stage Clinical ProgramTransitioning atebimetinib into a randomized Phase 3 and presenting Phase 2a survival data at ASCO are structural milestones. Moving from exploratory to registrational studies materially de-risks the program's clinical pathway and increases the potential for long-term commercialization or valuable partnerships.
Low Leverage / Solvency ProfileVery low reported leverage lowers bankruptcy and interest-rate vulnerability, giving strategic flexibility. For a cash-consuming biotech, low debt supports options for equity or partnership financings without heavy fixed-interest burdens, helping preserve runway for clinical programs.
Bears Say
No Meaningful RevenueWith effectively no revenue, the company cannot internally fund development; its value and operations depend entirely on successful trial outcomes or external capital. This creates lasting dilution and funding risk until a commercial product or durable partner revenue emerges.
Sustained Negative Cash FlowConsistently large negative operating and free cash flow implies ongoing cash burn and repeated financing needs. Over the medium term this raises execution risk: trials can be delayed, programs trimmed, or dilution increased, all of which materially affect long-term value creation prospects.
Equity Volatility And Small ScaleNotable equity swings and sharply negative returns reflect frequent financing and valuation volatility common to small biotechs. With only ~54 employees and no commercial track record, scaling operations and managing trial complexity present durable execution and governance risks if capital markets tighten.
Immuneering News
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $1.58 and its highest was $10.08 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $348.72M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is Aug 12, 2026 which is in 77 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on May 15, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.042.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.27.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 64,697,230 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went up 0.389%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (205.76% Upside)
$17.00 (205.76% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 181.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Bullish
Bullish news 79%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
242.20%
12-Months-Change
Fundamentals
Return on Equity
-0.11%
Trailing 12-Months
Asset Growth
323.84%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$17.00
▲(205.76% Upside)
Technical Analysis
Ownership Overview
9.47% Insiders
15.66% Mutual Funds
8.01% Other Institutional Investors
62.38% Public Companies and
Individual Investors